Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
Healthcare
$13.89 +1.20%
+$0.15 today
- Market cap
- $341.49M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
52W Low $8.46High $45.00
Volume 0.11M
Average 0.09M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$150.02M
FY 2025 · Annual
Investing Cash Flow
$54.10M
FY 2025 · Annual
-55.8% YoYFinancing Cash Flow
$50.41M
FY 2025 · Annual
+3701.4% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Depreciation & Amortization | 13.62M | 16.47M | 20.25M | 19.63M | 11.54M |
| Deferred Income Tax | 39.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 62.2M | 0 | 47.08M | 33.14M | 41.83M |
| Change in Working Capital | 4.02M | (82.02M) | 3.42M | (3.12M) | (9.89M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 91K | 667K | 1.46M | (3.23M) | (2.34M) |
| Other Working Capital | 3.92M | (82.68M) | 1.96M | 114K | (7.56M) |
| Other Non-Cash Items | 4.62M | 79.11M | 183K | 130.95M | 80.95M |
| Operating Cash Flow | (126.25M) | (169.56M) | (163.69M) | (162.39M) | (150.02M) |
| Capital Expenditures | (65.5M) | (24.28M) | (2.69M) | (464K) | (780K) |
| Acquisitions (Net) | 673.47M | 0 | 0 | (31.35M) | (41.2M) |
| Purchases of Investments | (673.47M) | (406.32M) | (476.88M) | (394.71M) | (259.71M) |
| Sales of Investments | 617.4M | 419.05M | 663.61M | 548.94M | 374.68M |
| Other Investing Activities | (673.47M) | 0 | 0 | 0 | (18.9M) |
| Investing Cash Flow | (121.57M) | (11.54M) | 184.05M | 122.42M | 54.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 391.8M | 11.1M | 2.2M | 1.4M | 50.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.44M | (461K) | (457K) | (76K) | (1K) |
| Financing Cash Flow | 401.24M | 10.64M | 1.74M | 1.33M | 50.41M |
| Effect of Forex Changes | 0 | 186K | (4K) | 0 | 0 |
| Net Change in Cash | 153.42M | (170.27M) | 22.09M | (38.64M) | (45.52M) |
| Free Cash Flow | (191.75M) | (193.83M) | (166.38M) | (162.86M) | (150.8M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$274.4M
+ D&A$11.5M
+ Stock-Based Comp$41.8M
+ Deferred Tax$0
- Working Capital-$9.9M
+ Other Non-Cash$81.0M
= Operating Cash Flow-$150.0M
- Capex-$780.0K
= Free Cash Flow-$150.8M
Analysis
FY2025 free cash flow is -$150.8M. FCF conversion is 54.9% of net income. Operating cash flow was -$150.0M, with capex of -$780.0K. The largest bridge item is Other Non-Cash at $81.0M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-3 | S-3 filing | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 |
Does LYEL generate free cash flow?
Lyell Immunopharma, Inc. (LYEL) generated -$150.80M of free cash flow in fiscal 2025.
How much operating cash flow does LYEL produce?
Operating cash flow was -$150.02M, before capital expenditures of $780,000.00.
Continue the stock analysis
Jump to another research area for this company.